TG Therapeutics Inc (TGTX)

[stockguard]

TG Therapeutics Inc. (NASDAQ:TGTX)

TG Therapeutics is a clinical-stage oncology company, but it’s yet another that presents a potential opportunity. The company recently released positive data from a pivotal trial of Umbralisib, its lead clinical candidate. This asset is key!

One of the most successful cancer drugs seen in recent year is Imbruvica, a tyrosine kinase inhibitor from Bruton. A short while ago, the company’s product became the first chemotherapy-free treatment option for newly diagnosed patients with a common form of leukemia. Unfortunately, about a third of patients discontinued treatment. Umbralisib has shown to only have a 13% discontinuation rate and could prove to be a disruptive force in the market.

Moreover, like the others on the list above, TG Therapeutics has an impressive pipeline. It consists of two late-stage assets in four clinical development programs and six early-stage assets. The strong pipeline and the potential of Umbralisib leads me to believe that TG Therapeutics is a strong opportunity in the market.
https://www.gurufocus.com/news/845511/5-oncology-companies-that-are-set-to-run